BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a biopharmaceutical company focused on developing medicines for genetic conditions, announced today that long-term efficacy and safety data in patients with ATTR-CM from the open-label extension (OLE) trial of ATTRibute-CM, its Phase 3 study of acoramidis, will be shared in a late-breaking oral presentation at the American College of Cardiology (ACC) Annual Scientific Sessions & Expo, taking place in New Orleans, Louisiana on March 28-30, 2026. Additionally, BridgeBio was selected to share three posters on additional OLE data and real-world survey findings.